Search - tctmd.com

Displaying 541 - 560 of 570

Sort: Relevancy | Date

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Daily News

房颤患者过渡治疗无法预防血栓栓塞，且会增加出血

Yael L. Maxwell

July 10, 2015

News Daily News

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Yael L. Maxwell

July 10, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

更新后的脑卒中指南支持对特定的患者使用支架拔出器

July 01, 2015

News Daily News

Updated Stroke Guidelines Back the Use of Stent Retrievers in Select Patients

July 01, 2015

News Daily News

Las Directrices Actualizadas en Materia de ACV Avalan el Uso de Recuperadores de Stent en Pacientes Seleccionados

July 01, 2015

News Daily News

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

June 25, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Daily News

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

En Análisis ACCOAST Identifica los Factores asociados a Más Riesgos Hemorrágicos en el Manejo de Cuadros de SCASEST

Todd Neale

June 22, 2015

News Daily News

ACCOAST分析发现了NSTE-ACS患者更高出血风险的有关因素

Todd Neale

June 22, 2015

News Daily News

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Todd Neale

June 22, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

Presentation

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Presenter: Patricia A. Cowper

February 02, 2015

News Daily News

Long-term Ticagrelor Therapy Cost-Effective in US Patients

L.A. McKeown

February 02, 2015

Advertisement

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

房颤患者过渡治疗无法预防血栓栓塞，且会增加出血

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

更新后的脑卒中指南支持对特定的患者使用支架拔出器

Updated Stroke Guidelines Back the Use of Stent Retrievers in Select Patients

Las Directrices Actualizadas en Materia de ACV Avalan el Uso de Recuperadores de Stent en Pacientes Seleccionados

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

En Análisis ACCOAST Identifica los Factores asociados a Más Riesgos Hemorrágicos en el Manejo de Cuadros de SCASEST

ACCOAST分析发现了NSTE-ACS患者更高出血风险的有关因素

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Long-term Ticagrelor Therapy Cost-Effective in US Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content